Filing Details
- Accession Number:
- 0001140361-12-038798
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-08-29 14:31:48
- Reporting Period:
- 2012-08-27
- Filing Date:
- 2012-08-29
- Accepted Time:
- 2012-08-29 14:31:48
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1184151 | R Conan Deady | One Idexx Drive Westbrook ME 04092 | Corp Vp, General Counsel & Sec | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-08-27 | 3,448 | $56.95 | 17,192 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-08-27 | 9,194 | $94.81 | 7,998 | No | 4 | S | Direct | |
Common Stock | Disposition | 2012-08-29 | 2,000 | $95.31 | 5,998 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Acquisiton | 2012-08-27 | 3,448 | $0.00 | 3,448 | $56.95 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
1,693 | 2015-02-13 | No | 4 | M | Direct |
Footnotes
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $94.80to $94.97, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- Grant of options to buy shares of common stock becomes exercisable as to 3,449 shares on 02/14/2009 and 02/14/2010, 3,448 shares on 02/14/2011 and 02/14/2012, and the remaining 1,693 shares on 02/14/2013.